RARE Stock: Price, Earnings History and SEC Filings
Ultragenyx Pharmaceutical Inc. (RARE) last traded at $16.10, down 4.05% on the latest session and up 7.1% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-0.90 against an analyst estimate of $-1.27, a beat of 29.1%.
$16.10 -4.05%
1 month+7.12%
52-week high$39.89
52-week low$12.73
Volume2.33M
ExchangeNasdaqGS
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
RARE earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 4, 2026 | $-0.90 | $-1.27 | +29.13% |
| Mar 2026 | May 5, 2026 | $-1.84 | $-1.55 | -18.71% |
| Dec 2025 | Feb 12, 2026 | $-1.29 | $-1.20 | -7.50% |
| Sep 2025 | Nov 4, 2025 | $-1.81 | $-1.23 | -47.15% |
RARE beat the analyst EPS estimate in 1 of its last 4 reported quarters. Source: Nasdaq.
Latest SEC filings for RARE
SEC filing data is not available right now. You can search for RARE on SEC EDGAR.
RARE news
- USA Rare Earth (USAR) Stock Dropped, What Is Behind The Latest Attention?Nov 1, 2026 · finance.yahoo.com
- Ultragenyx (RARE) vs. SRPT and BMRN: Can Upcoming Drug Approvals Unlock the Next Phase of Biotech Growth?Oct 30, 2026 · finance.yahoo.com
- What Needs To Be True To Buy USA Rare Earth Stock?Oct 28, 2026 · finance.yahoo.com
- Analysts Estimate Cytek Biosciences, Inc. (CTKB) to Report a Decline in Earnings: What to Look Out forOct 28, 2026 · finance.yahoo.com
- GSK (GSK) Q3 Earnings and Revenues Beat EstimatesOct 28, 2026 · finance.yahoo.com
- Has The Story Under Krystal Biotech Stock Run Out?Oct 28, 2026 · trefis.com
- Ultragenyx to Host Conference Call for Third Quarter 2026 Financial Results and Corporate UpdateOct 27, 2026 · finance.yahoo.com
- Broadcom upgraded, HubSpot downgraded: Wall Street's top analyst callsOct 27, 2026 · finance.yahoo.com
About Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc. (RARE) is a US-listed public company on Nasdaq.